PT-141 has human evidence behind it, but that evidence does not validate every promise made under its name. Bremelanotide, marketed in the United States as Vyleesi, improved desire and distress scores in some premenopausal women. This demonstrates neither universal efficacy nor the equivalence of a spray or research vial to this medicine.
Documentary status checked on October 15, 2026: no corresponding medicinal product found in the French and EMA data consulted. US approval does not amount to French approval. If reduced desire concerns you, the useful next step is to prepare for a consultation, not hunt for a dosing regimen on a forum.
PT-141, bremelanotide and Vyleesi: three names, not three guarantees
PT-141 is the development code for bremelanotide, a synthetic cyclic peptide. Vyleesi is a US medicinal product containing this substance, with its own formulation, subcutaneous delivery device, indication and prescribing information. A substance name on a vial does not demonstrate that its contents, manufacturing or exposure in the body are equivalent.
According to the US prescribing information consulted, the indication covers hypoactive sexual desire disorder that is acquired and generalized in premenopausal women, associated with marked distress or interpersonal difficulty. “Acquired” means it developed after a period without this problem. “Generalized” means it is not limited to a partner, situation or type of stimulation.
The indication excludes reduced desire explained by a medical or psychiatric condition, relationship difficulties, or the effects of a medicine or substance. The prescribing information does not indicate it for men, postmenopausal women or enhanced sexual performance. Less frequent sexual desire is therefore not, by itself, this diagnosis.
Desire and erection: what trials measure
Sexual desire means sexual interest or motivation. An erection is a physiological response. Subjective arousal, orgasm, pain and satisfaction are other dimensions again. Improvement in one does not guarantee improvement in the others.
Two distinct clinical questions
More desire and an erection are not the same outcome
- DesireSexual interest and associated distress, assessed using questionnaires among other measures.
- ErectionRigidity, duration or erectile function, depending on the study protocol.
Bremelanotide activates several melanocortin receptors. The involvement of central pathways, particularly MC4R, explains the scientific interest. But the prescribing information states that the exact mechanism behind improvement in the desire disorder remains unknown. Presenting it as an exclusively selective MC4R agonist oversimplifies its pharmacology.
To put the problem in context before discussing a substance, the guide to low libido in women and its possible causes · FR helps distinguish desire, pain, context and treatments.
Human findings: populations, outcomes, routes and limitations
Here are the data that actually allow the claims to be compared:
| Population studied | Outcome measured | Route and study | Level of evidence and limitation |
|---|---|---|---|
| Premenopausal women with acquired, generalized desire disorder | Desire and associated distress scores | Subcutaneous, two phase 3 RECONNECT trials, 24 weeks | Randomized placebo-controlled trials, 1,267 participants randomized. Findings apply to this selected population |
| Participants who completed the main phase | Long-term tolerability and reported scores | Subcutaneous, 52-week open-label extension | Useful follow-up, but without placebo and with selection of those who continue |
| 19 men with erectile dysfunction who reported responding to standard treatments | Erectile response measured by RigiScan during visual stimulation | Intranasal combined with sildenafil, 2005 crossover trial | Exploratory signal for erection. Demonstrates neither an isolated effect on libido nor the general safety of a combination |
| 18 premenopausal women with arousal disorder | Subjective sexual response in an experimental setting | Intranasal, 2006 crossover trial | Small exploratory trial, different from the phase 3 trials and their population’s diagnosis |
| Buyer of a current research spray or vial | No clinical outcome verified for the product sold in this audit | Variable commercial presentation | Reference to a studied substance does not demonstrate product equivalence |
The two RECONNECT trials and their extension were reviewed in full text. For the nasal trials from 2005 in men and 2006 in women, only abstracts were obtained: they serve to describe the scope, not to establish commercial equivalence or a protocol.
A statistical effect on scores, not a performance promise
In the pooled RECONNECT analysis, the mean advantage over placebo is 0.35 points on the FSFI desire domain and −0.33 points on the FSDS-DAO distress item. These are differences on two separate scales, not percentage increases in libido. The FSFI desire domain ranges from 1.2 to 6, and the distress item from 0 to 4.
The number of satisfying sexual events, a prespecified secondary outcome, does not increase significantly compared with placebo. An exploratory analysis of their proportion does not replace this result. The trials can therefore support improvement in reported desire and distress without demonstrating “more satisfying sexual encounters” according to the prespecified outcome.
The limitations matter: industry funding, a predominantly white population, exclusion of several psychiatric disorders and treatments, and more withdrawals in the bremelanotide groups. The open-label extension does not remove these limitations or demonstrate indefinite safety.
Data in men do not automatically extend the indication in women
The trial in men cited in the table measures an erectile response over a short period and tests a combination. It does not answer the question “will a man with reduced desire benefit from PT-141 alone?” The same distinction prevents turning the US approval for women into a recommendation for men.
Two 2026 reviews provide context: the review of registered trials on female desire disorder, reviewed in full, describes heterogeneous outcomes and safety reporting. The narrative review of peptides in sexual medicine, checked through its PubMed abstract, distinguishes treatments established for certain indications from insufficiently validated uses. Neither review is a new trial demonstrating the efficacy of a retail spray.
Sprays and vials: auditing marketing promises
Documentary review dated October 15, 2026 of a French Peptilab France vial listing and a European NOVA Labs spray listing. No product was purchased or analyzed. The claims below are those observed on the pages, not properties I certify:
| Claim observed | What it does not demonstrate | Verification needed to go further |
|---|---|---|
| Reference to FDA approval of Vyleesi on a research vial listing | Approval of the vial sold, or its equivalence to the medicine | Identification of the approved medicinal product and its manufacturer, formulation and regulatory pathway |
| High HPLC purity and an advertised certificate | Human efficacy, the dose actually delivered and full pharmaceutical quality | Identity, content, batch, process, stability and controls appropriate to the route |
| Spray presented as ready to use | Exposure equivalent to the subcutaneous injection used in phase 3 | Studies of the formulation and its bioavailability, not simply a matching name |
| Presentation as a selective MC4R agonist | Absence of activity at other receptors or absence of risk | Comparison with the prescribing information, which describes several receptor subtypes |
| Research terminology paired with suggested use related to sexual function | A prescribing framework, individual benefit or French approval | Relevant regulatory documents and human data for the product concerned |
The audit examines the leap from these arguments to the clinical conclusion. It proves neither falsification nor contamination of any specific batch. A certificate advertised on a page must be interpreted according to what was actually tested, on which sample and for which product.
The guide to certificates, sterility and online research products · FR explains why purity, identity, content, endotoxins and sterility are different checks. None of these checks replaces a clinical equivalence trial.
Adverse effects, cardiovascular precautions and interactions
The US prescribing information for Vyleesi, revised in November 2025, documents the risks of the medicinal product studied. The frequencies cannot be transferred to a vial or spray whose composition and exposure are unknown.
The following effects were reported in controlled trials:
| Effect | Vyleesi | Placebo |
|---|---|---|
| Nausea | 40.0% | 1.3% |
| Flushing | 20.3% | 0.3% |
| Headache | 11.3% | 1.9% |
| Vomiting | 4.8% | 0.2% |
The document also reports administration-site reactions and discontinuations due to adverse effects. Uncontrolled hypertension and known cardiovascular disease are contraindications. Blood pressure may rise transiently and heart rate may fall. A mean change considered modest in a selected trial does not guarantee safety for someone at risk.
Localized hyperpigmentation may affect areas including the face, gums or breasts. Its resolution after discontinuation has not been confirmed in everyone affected. This risk is not a desirable cosmetic effect to brush off.
The medicine can slow gastric emptying and alter the absorption of oral treatments. The prescribing information particularly flags oral naltrexone used for alcohol or opioid addiction, exposure to which may decrease, with a risk of treatment failure. Do not stop a prescribed medicine to try a peptide: have a doctor or pharmacist review all your treatments.
Pregnancy, plans to become pregnant, breastfeeding and severe renal or hepatic impairment also require specific assessment. The prescribing information calls for discontinuation if pregnancy is suspected and highlights the lack of data during breastfeeding. These situations cannot be solved with a “more cautious” dose found online.
Status in France: dated verification and limitations
The audit on October 15, 2026 used the names brémélanotide/bremelanotide, PT-141/PT141 and Vyleesi in the relevant data and search engines:
| Source | Check | Finding and limitation |
|---|---|---|
| French public medicines database | Medicinal product and composition files, normalized variants without accents or hyphens | No match. Database of medicines marketed currently or within the past three years |
| ANSM website | Searches for brémélanotide, bremelanotide and Vyleesi | No results under these names. A document search engine does not replace a marketing authorization register |
| EMA | Official catalogue of medicines under the centralized procedure, updated on the day of the check | No match. This catalogue does not cover all national procedures |
| DailyMed, US prescribing information | Vyleesi indication, route, contraindications and warnings | US approval and information, not evidence of French marketing authorization |
The data are available in the French medicines database, the ANSM search engine and the official EMA exports. A substance name in a trial registry would not constitute marketing authorization either.
The conclusion is therefore limited but useful: no corresponding medicinal product was found within this scope, and reference to Vyleesi does not justify presenting an online offering as a medicine authorized in France. This finding is neither an ANSM attestation nor an opinion on every exceptional access, importation or possession arrangement.
Reduced desire: preparing for a consultation
The starting point is what bothers you, not a target number of sexual encounters. The clinical assessment of desire disorder examines factors including health, treatments, relationship context and psychological factors. Erectile difficulty, pain and reduced desire do not automatically call for the same care.
Prepare this information for your doctor, gynecologist or a professional trained in sexual health:
- How long the change has been present, and whether it is constant or linked to certain situations.
- What personally concerns you: desire, arousal, erection, orgasm, pain or distress.
- Treatments, supplements, substances and research products used recently.
- Your cardiovascular, blood pressure, kidney or liver history and the possibility of pregnancy.
- Any effects already experienced after using a product, along with its name, batch and packaging if available.
Ask which causes are plausible, which options have evidence for your profile, and how benefit would be assessed. The consultation must also respect your autonomy: a bodily response or a treatment creates no sexual obligation.
After exposure, chest pain, difficulty breathing or feeling severely unwell warrant contacting emergency services on 15 or 112 in France. Do not take the product again to test whether a symptom returns.
